拓扑替康联合顺铂治疗小细胞肺癌的临床研究

Clinical Study on Topotecan Combined with Cisplatin in the Treatment of Small-Cell Lung Cancer(SCLC)

摘要: 目的　评价拓扑替康联合顺铂治疗小细胞肺癌 (SCLC)的疗效及安全性。方法　经病理组织学或细胞学确诊的 19例, 用药方法为拓扑替康 (Topotecan, TPT) 1.0mg/ (m2 ·d), 静滴 30分钟, 连用 5天 ;顺铂 (Cisplatin, DDP) 30mg/m2 静滴, 连用 3天, 每 3周一疗程。治疗 2疗程评价疗效。结果　 19例可评价病人。总有效率为 4 7.6 %, 对初治及复治SCLC的有效率分别为 6 6 .7%、38.5 %。主要毒副反应为骨髓抑制。Ⅲ～Ⅳ度中性粒细胞减少及血小板减少的发生率分别为 5 2 .6 %、4 2 .1%。贫血发生率为6 3.5 %, 其中 2 6 .3%为中重度贫血。非血液学毒性较轻, 一般可耐受。结论　拓扑替康联合顺铂为治疗SCLC的有效化疗方案, 特别对复发的病例疗效较好。主要毒性为骨髓抑制, 用药时应予足够重视。

Abstract: Objective To evaluate the efficacy and safty of combined topotecan(TPT) with cisplatin(DDP) in the treatment of small-cell lung cancer(SCLC). Methods 19 patients with SCLC diagnosed by pathology or cytology were enrolled into the study. The patients were treated with TPT 1.0mg/(m2·d) intravenously(IV) during 30 minutes on d 1～5 and DDP (30mg/m2 IV on d 1～3) of 3-week regiment. The efficacy was evaluated after 2 cycles of treatment. Results 19 of all the cases could be evaluated. The total resp...